The Claim

GLP-1 receptor agonists reduce the absolute risk of major adverse cardiovascular events by 2.12% over three years in type 2 diabetes patients with pre-existing atherosclerotic cardiovascular disease, compared to a 0.92% reduction in those without pre-existing atherosclerotic cardiovascular disease, due to higher baseline risk.

Source: 1411-P: Relative and Absolute Risk Reduction for MACE in Cardiovascular Outcomes Trials with GLP-1 Receptor Agonists in Type 2 Diabetes Patients with and without ASCVD at Baseline

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
60score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Quantitative
1 study reviewed
In plain English

In people with type 2 diabetes and existing heart disease, GLP-1 receptor agonists lower the chance of serious heart events by 2.12% over three years. In people with type 2 diabetes but no prior heart disease, the reduction is 0.92% over the same period.

See the scientific wording

The absolute benefit of GLP-1 receptor agonists in preventing major adverse cardiovascular events is significantly greater in type 2 diabetes patients with pre-existing atherosclerotic cardiovascular disease than in those without, due to higher baseline risk, with absolute risk reductions of 2.12% versus 0.92% over three years.

Why this might work

In people with existing heart disease, GLP-1 receptor agonists reduce inflammation in artery walls and make fatty plaques more stable, which prevents them from rupturing and causing heart attacks or strokes. This effect is stronger in those with more advanced disease because their arteries have more inflammation and unstable plaques to begin with.

Supported mechanismbased on 1 study

What the research says

1 study

  1. Study: 1411-P: Relative and Absolute Risk Reduction for MACE in Cardiovascular Outcomes Trials with GLP-1 Receptor Agonists in Type 2 Diabetes Patients with and without ASCVD at Baseline

    GLP-1 drugs prevent more heart problems in diabetic patients who already have heart disease because they’re at higher risk to begin with — even though the percentage drop in risk is similar for everyone. For every 47 high-risk patients treated, one heart event is prevented, versus 109 low-risk patients to prevent one.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.